A systematic and regular laboratory hormonal follow-up including 8 am cortisol assessment for patients receiving ICI is therefore necessary, not only for patients treated with CTLA4 inhibitors but also for those treated with PD1/PDL1 inhibitors, even if hypophysitis remains less frequent in such patients. This evidence concerns the gene CD274 and hypophysitis.